A scoping review mapped out 34 clinical trials testing psychedelics for substance use disorders, from alcohol and nicotine to opioids and stimulants. Most of the promising results so far come from psilocybin, which helped people reduce drinking and quit smoking in long-term follow-ups. On the brain level, psychedelics appear to steady dopamine signaling in the reward system, a mechanism that may reduce cravings and relapse. While early results are encouraging, most trials are still small or open-label, meaning more rigorous studies are needed.